Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXON ENTERPRISE, INC.AXON · Entity 567 | Director | May 12, 2023 | May 16, 2023 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXON ENTERPRISE, INC.
Report date May 12, 2023 · Filed May 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,135 |
Reported balance
After 2023-05-12 transaction · row 1
1 source rowRow 1 · 2023-05-12 · Grant · Acquired 993 · Balance 11,135 F1: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2022 Stock Incentive Plan. The grant is scheduled to vest on May 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2022 Stock Incentive Plan. The grant is scheduled to vest on May 13, 2024.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,295 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 27,295 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 28, 2026 20:58 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000107 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,295 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:18 UTC | HAEMONETICS CORP HAE · Entity 3953 | PurchaseCommon Stock | 1,400 | $70.56 | $98,784.00 |
DisclosureSEC source: 0000313143-25-000078 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,757 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019596 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,357 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021035 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,664 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022202 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,457 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 12, 2023 Filed May 16, 2023 00:30 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | GrantCommon Stock | 993 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-008073 · form4-05162023_120517.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,135 F1 · shares: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2022 Stock Incentive Plan. The grant is scheduled to vest on May 13, 2024. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 23:09 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | SaleCommon Stock | 3,457 | $220.72 | $763,042.87 |
DisclosureSEC source: 0001415889-23-004519 · form4-03082023_110339.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,142 Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 23:09 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | SaleCommon Stock | 92 | $220.85 | $20,318.20 |
DisclosureSEC source: 0001415889-23-004519 · form4-03082023_110339.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,599 Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,016 | $73.71 | $590,859.36 |
DisclosureSEC source: 0001127602-22-021087 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,231 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.41 to $74.25, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020701 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,247 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:42 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | SaleCommon Stock | 3,159 | $102.82 | $324,795.74 |
DisclosureSEC source: 0001415889-22-006379 · form4-06092022_010632.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,691 F1 · price: The transaction was executed in multiple trades at prices ranging from $102.74 to $102.95. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2022 Filed May 23, 2022 23:15 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | GrantCommon Stock | 2,013 | $99.40 | $200,092.20 |
DisclosureSEC source: 0001415889-22-005551 · form4-05232022_040555.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,850 F1 · shares: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2019 Stock Incentive Plan. The grant is scheduled to vest on May 20, 2023. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023396 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,517 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 20:06 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | GrantCommon Stock | 1,434 | $139.48 | $200,014.32 |
DisclosureSEC source: 0001415889-21-002731 · form4-06012021_040628.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,837 F1 · shares: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2019 Stock Incentive Plan. The grant is scheduled to vest in three equal installments beginning on May 27, 2022. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · derivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests 100% on the first anniversary of the date of grant. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 11,813 | $55.10 | $650,896.30 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,440 F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 26, 2021 Filed May 28, 2021 20:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,557.38 |
DisclosureSEC source: 0001127602-21-018310 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:05 UTC | AXON ENTERPRISE, INC. AXON · Entity 567 | SaleCommon Stock | 4,204 | $124.94 | $525,260.37 |
DisclosureSEC source: 0001415889-21-002470 · form4-05142021_040501.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,403 Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:32 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000360 · form4-01212021_010145.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,607 F1 · kind: Represents a charitable gift to The Minneapolis Foundation. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 21:43 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | SaleCommon Stock | 2,993 | $120.44 | $360,476.92 |
DisclosureSEC source: 0001415889-20-002650 · form4-11172020_011124.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,607 Read SEC document |
| September 14, 2020 Filed May 14, 2021 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 167 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016857 · form5.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 11, 2020 Filed May 14, 2021 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016857 · form5.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,067 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021981 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,401 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:30 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GrantCommon Stock | 2,107 | $75.96 | $160,047.72 |
DisclosureSEC source: 0001415889-20-001433 · form4-06022020_040606.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,600 F1 · shares: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2019 Stock Incentive Plan. The grant is scheduled to vest in three equal installments beginning on May 29, 2021. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001127602-20-013642 · form4.xml · derivative · entry 5 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2020-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests 100% on the first anniversary of the date of grant. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,329 | $102.00 | $441,558.00 |
DisclosureSEC source: 0001127602-20-013642 · form4.xml · nonDerivative · entry 4 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,418 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 6,573 | $102.00 | $670,446.00 |
DisclosureSEC source: 0001127602-20-013642 · form4.xml · nonDerivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,747 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 6,573 | $45.45 | $298,742.85 |
DisclosureSEC source: 0001127602-20-013642 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 31, 2019 Filed Apr 13, 2020 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-013642 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,747 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 21:57 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | SaleCommon Stock | 4,168 | $64.30 | $267,987.40 |
DisclosureSEC source: 0001069183-19-000147 · wf-form4_157376861571706.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,493 F1 · price: The transaction was executed in multiple trades at prices ranging from $64.29 to $64.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025269 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,617 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 22:17 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GrantCommon Stock | 2,396 | $66.78 | $160,004.88 |
DisclosureSEC source: 0001069183-19-000088 · wf-form4_155960023001479.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,661 F1 · shares: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2019 Stock Incentive Plan. The grant is scheduled to vest in three equal installments beginning on May 31, 2020. Read SEC document |
| May 21, 2019 Filed May 24, 2019 20:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019898 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,157 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:42 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GiftCommon Stock | 952 | $0.00 | $0.00 |
DisclosureSEC source: 0001069183-19-000072 · wf-form4_155855772231354.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,265 Read SEC document |
| December 24, 2018 Filed May 13, 2019 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-018356 · form5.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,606 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · derivative · entry 5 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 10,707 | $114.00 | $1,220,598.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 4 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,748 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 21:43 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GiftCommon Stock | 1,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001069183-18-000093 · wf-form4_153557897095888.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,217 Read SEC document |
| August 20, 2018 Filed Aug 20, 2018 21:53 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | SaleCommon Stock | 7,097 | $64.34 | $456,620.98 |
DisclosureSEC source: 0001069183-18-000089 · wf-form4_153480198830750.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,105 Read SEC document |
| August 16, 2018 Filed Nov 9, 2018 21:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,259 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 14, 2018 Filed Nov 9, 2018 21:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,459 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024061 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,459 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| May 24, 2018 Filed May 24, 2018 22:47 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GrantCommon Stock | 2,577 | $62.08 | $159,980.16 |
DisclosureSEC source: 0001069183-18-000070 · wf-form4_152720200566848.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,205 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 7,118 | $0.00 Strike: $34.41 | $0.00 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · derivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,118 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 7,118 | $63.00 | $448,434.00 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,763 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 01:56 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 7,118 | $34.41 | $244,894.79 |
DisclosureSEC source: 0001127602-18-000896 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise and sale pursuant to a trading plan which was established consistent with the requirements of Rule 10b5-1. Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 21:22 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,329 | $39.27 | $169,999.83 |
DisclosureSEC source: 0001127602-17-024392 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,763 F1 · shares: Restricted Stock Unit grant which vests 100% on the first anniversary of the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:10 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GrantCommon Stock | 6,403 | $24.99 | $160,010.97 |
DisclosureSEC source: 0001069183-17-000095 · wf-form4_149582939346095.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,628 F1 · security: Time-vested restricted stock units granted to the reporting person pursuant to the TASER International, Inc. 2016 Stock Incentive Plan. The grant is scheduled to vest in three equal annual installments beginning on May 15, 2018. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,580 | $0.00 Strike: $27.24 | $0.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · derivative · entry 23 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,580 shares Expires 2017-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.